96 results on '"Wojdyla, Daniel"'
Search Results
2. Case Volumes and Outcomes Among Early-Career Interventional Cardiologists in the United States
3. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention
4. TCT-406 Effect of Antithrombotic Strategies on Total Outcome Events in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS
5. Digoxin and Mortality in Patients With Atrial Fibrillation
6. WOMEN IN EXPLORER-HCM HAD MORE SEVERE HEART FAILURE AT BASELINE BUT SIMILAR, OR GREATER, RESPONSE TO MAVACAMTEN
7. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS OF OLDER AGE AND LONGER DURATION OF DIAGNOSIS: ANALYSIS OF THE EXPLORER-HCM TRIAL
8. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS WITH OR WITHOUT HYPERTENSION: ANALYSIS OF THE EXPLORER-HCM TRIAL
9. OBSTRUCTIVE HCM PATIENTS IN EXPLORER-HCM WITH HIGH LEFT VENTRICULAR FILLING PRESSURES HAD MORE SEVERE HEART FAILURE BUT SIMILAR OR GREATER RESPONSE TO MAVACAMTEN
10. TCT-20 Relative Benefit of Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Randomized Earlier Versus Later After Index Coronary Event: Insights From the AUGUSTUS Trial
11. TCT-586 Outcomes and Institutional Variation in Arterial Access Choice Among Patients With Acute Myocardial Infarction and Cardiogenic Shock Undergoing PCI: An Analysis From the CathPCI Registry
12. TCT-1 Bleeding in Patients With Atrial Fibrillation and Acute Coronary Syndrome or PCI Treated With Antithrombotic Therapy: Insights From the AUGUSTUS Trial
13. GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL
14. CLINICAL CHARACTERISTICS AND OUTCOMES AMONG ASIANS UNDERGOING ANTITHROMBOTIC THERAPY FOLLOWING ACUTE CORONARY SYNDROME
15. MODIFIED ON-TREATMENT ANALYSIS OF THE EFFECTS OF TORSEMIDE VS FUROSEMIDE AFTER DISCHARGE IN PATIENTS HOSPITALIZED WITH HEART FAILURE: RESULTS FROM TRANSFORM-HF
16. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance
17. TCT-167 Utilization Rates and In-Hospital Outcomes Associated With Intravascular Imaging–Guided PCI in the USA: An Analysis of the NCDR CathPCI Registry
18. EFFECT OF APIXABAN VERSUS VITAMIN K ANTAGONIST AND ASPIRIN VERSUS PLACEBO ON DAYS ALIVE AND OUT OF HOSPITAL IN THE AUGUSTUS RANDOMIZED CONTROLLED TRIAL
19. NATIONWIDE TRENDS AND OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTIONS FOLLOWING DIAGNOSTIC ANGIOGRAPHY PERFORMED BY NON-INTERVENTIONAL CARDIOLOGIST VERSUS INTERVENTIONALISTS: INSIGHTS FROM THE CATHPCI REGISTRY
20. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
21. APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL
22. THE IMPACT OF HYPERLIPIDEMIA ON CARDIOVASCULAR RISK IN OLDER ADULTS AGE ≥ 75: RESULTS FROM THE NHLBI POOLED COHORTS
23. PREVALENCE & CONTROL OF EXTREMELY HIGH LDL CHOLESTEROL: AN ANALYSIS IN >10,000,000 INDIVIDUALS ACROSS 429 HEALTH SYSTEMS
24. RECALLED ICD GENERATORS IN THE NCDR-ICD REGISTRY: OUTCOMES AND SURVEILLANCE IMPLICATIONS
25. TRANSFUSIONS, WITH OR WITHOUT CONCOMITANT BLEEDING, ARE ASSOCIATED WITH HIGH SHORT-TERM MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION
26. COMPARISON OF RATES OF BLEEDING AND VASCULAR COMPLICATIONS BEFORE, DURING, AND AFTER TRIAL ENROLLMENT IN THE SAFE-PCI TRIAL FOR WOMEN
27. AD HOC PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY
28. THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY
29. ASSOCIATION BETWEEN OPTIMISM AND OUTCOMES IN PATIENTS WITH CHRONIC ANGINA
30. TCT-339 Types of Myocardial Infarction in Patients with Peripheral Artery Disease: Insights From EUCLID
31. Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States
32. CLOPIDOGREL IS NOT COMMONLY USED BUT ASSOCIATED WITH LESS RE-HOSPITALIZATION IN PATIENTS WITH PERIOPERATIVE MYOCARDIAL INFARCTION FOLLOWING CABG SURGERY
33. USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL
34. RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
35. EFFECTS OF AGE AND COMORBIDITIES ON OUTCOMES IN PATIENTS WITH HEART FAILURE FROM HF-ACTION
36. TCT-244 Lower rates of repeat revascularization among patients with prior coronary artery bypass grafting is partly due to lack of adequate target vessels
37. AEROBIC EXERCISE TRAINING AND HEALTH STATUS IN AMBULATORY HEART FAILURE PATIENTS WITH A REDUCED EJECTION FRACTION: AN ANALYSIS FROM THE HF-ACTION TRIAL
38. APIXABAN VERSUS WARFARIN FOR PATIENTS WITH RECENT ONSET ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE TRIAL
39. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes
40. Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation
41. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
42. POORLY CONTROLLED BLOOD PRESSURE IS INDEPENDENTLY ASSOCIATED WITH A 50% HIGHER RISK OF STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL
43. APIXABAN COMPARED WITH WARFARIN IN PATIENTS WITH DIABETES AND NONVALVULAR ATRIAL FIBRILLATION IN THE ARISTOTLE TRIAL
44. Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial
45. Factors Associated With Major Bleeding Events
46. APIXABAN IS EFFICACIOUS AND SAFE IN PATIENTS WITH ATRIAL FIBRILLATION USING CONCOMITANT AMIODARONE: AN ANALYSIS FROM THE ARISTOTLE TRIAL
47. CHARACTERIZATION OF THE MYOCARDIAL INFARCTION ENDPOINTS, IMPACT OF EVENT ADJUDICATION, AND TICAGRELOR EFFECTS IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL
48. LOST TO FOLLOW-UP IN CONTEMPORARY GLOBAL CARDIOVASCULAR RANDOMIZED CLINICAL TRIALS
49. Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction
50. EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.